HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cantarini, L Articles by Galeazzi, M Search for Related Content PubMed PubMed Citation Articles by Cantarini, L Articles by Galeazzi, M

Sulfasalazine-induced immune thrombocytopenia

¹ Rheumatology Unit, Department of Clinical Medicine and Immunological Sciences, University of Siena, Italy
² Department of Clinical and Experimental Medicine, University of Verona, Italy

Correspondence to:
Correspondence to:
Dr Ilaria Tinazzi
Department of Clinical and Experimental Medicine, University of Verona, Pz.le Scuro,10 37134; Verona, Italy; ilariatinazzi{at}yahoo.it

Sulfasalazine is a well established disease-modifying anti-rheumatic drug commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. Sulfasalazine was generally well tolerated in clinical trials, the most frequently reported adverse effects being adverse gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. We are now reporting the first case of autoimmune thrombocytosis following sulfasalazine treatment.

Abbreviations: NSAIDs, non-steroidal, anti-inflammatory drugs; SLE, systemic lupus erythematosus; TNF, tumour necrosis factor